Targets › IL31RA
1 program from 1 company in 6 trials: 3 Phase 3, 3 Phase 2; Immunology; next expected readout Dec 2026.
Functions as a membrane-bound signal-transducing subunit of the IL31 receptor complex (heterodimer composed of OSMR and IL31RA) which binds IL31. Functionally, IL31 signaling via OSMR/IL31RA is particularly important in skin immunity. (UniProt, Q8NI17)
Open in Phaseline: the race on IL31RA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Galderma R&D | Nemolizumab Interleukin-31 receptor subunit alpha inhibitor | IL31RA | Phase 3 | Moderate-to-Severe Atopic Dermatitis; Prurigo Nodularis; Atopic Dermatitis; Chronic Pruritus of Unknown Origin … | Dec 2026 |
Moderate-to-Severe Atopic Dermatitis (2) Prurigo Nodularis (1) Atopic Dermatitis (1) Chronic Pruritus of Unknown Origin (1) Systemic Sclerosis (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.